Monday, 11 March 2013

ReNeuron wins grands totalling £1.2 million

ReNeuron was recently awarded with two grants totalling 1.2 million pounds to further develop their stem cell-based treatments.

The first grant, of £0.4m, was awarded by the UK Biomedical Catalyst (UBC), an integrated translational funding program providing support to the "best life science opportunities arising in the UK". The UBC is operated by the Medical Research Council and the Technology Strategy Board.

According to ReNeuron's announcement, UBC's fund will be used in the early development of ReNeuron’s product "ReN009", a stem cell treatment for acute limb ischaemia, which occurs when there is an sudden lack of blood flow to a limb due to either an embolism or thrombosis.

The second grant, of £0.8m, again by the UBC will be used to fund the pre-clinical development of ReN003, a stem cell therapy for retinitis pigmentosa, a degenerative eye disease that causes severe vision loss and many times blindness.

Michael Hunt, ReNeuron's Ceo, said:

"We are delighted to have been successful in winning the two grants we applied for in the current round of the Biomedical Catalyst funding competition."

Interview with Michael Hunt

ReNeuron is a clinical-stage stem cell business mainly focused in the development of "novel stem cell therapies targeting areas of significant unmet or poorly met medical need". Reneuron is currently running the PISCES study (Pilot Investigation of Stem Cells in Stroke), a clinical trial of a neural stem cell-based treatment for disabled stroke patients.


No comments:

Post a Comment

Please note that we don't offer any kind of medical advice. Questions requesting specific medical advice (e.g. "where can I get this treatment", "will this cure XXX condition" etc) will be published but most probably ignored by the site's administrators. :)